


## Firmonertinib

Cat. No.:	HY-112870
CAS No.:	1869057-83-9
Molecular Formula:	C <sub>28</sub> H <sub>31</sub> F <sub>3</sub> N <sub>8</sub> O <sub>2</sub>
Molecular Weight:	568.59
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Firmonertinib (Alflutinib) is a potent inhibitor of EGFR. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC) <sup>[1]</sup> .
IC <sub>50</sub> & Target	EGFR
In Vitro	Firmonertinib is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Patent. US20220177473A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA